Its being studied for both diabetes and weight management, with an FDA decision expected in late 2026
Several guidelines currently recommend GLP-1 RAs as add-on therapy to almost all diabetic treatments (with the exception of dipeptidyl peptidase-4 [DPP-4] inhibitors) and even as monotherapy to those intolerant to metformin
The catalytic activity of the molecule appears to be involved in at least some of these actions, and several endogenous substrates have been identified, although a role for protease-independent functions related to metabolic homeostasis has also been suggested
This approach extends beyond weight management into broader metabolic care
" The rise of GLP-1 medications is more than a healthcare breakthroughits a strategic advantage for organizations committed to employee health
Counter frozen meals are widely available at over 1,650 Target locations, Kroger, and Lidl stores, as of March 2026